The biotechnology company AcuCort

Develops and commercializes smart drugs that meet the patient’s need for a user-friendly and effective treatment.

About AcuCort

Financial Reports

^{Our financial reports are only available in Swedish.}

August 12, 2022 Regulatory

AcuCort publishes the Interim Report for the second quarter 2022 (in Swedish)

April 28, 2022 Regulatory

AcuCort publishes the Interim Report for the first quarter 2022 (in Swedish)

Calendar

29 September

September 29, 2022

CEO presents AcuCort at Nordic Life Science Days in Malmö at 10:00 am
Add to calendar
11 November

November 11, 2022

Interim Report January – September 2022
Add to calendar

Press releases

September 28, 2022 Non Regulatory

AcuCort reports positive results from the company’s questionnaire study about allergy treatments

September 27, 2022 Regulatory

AcuCort receives marketing authorization for the drug Zeqmelit by the Norwegian Medicines Agency

All press releases

acucort-ceo-homepage-module

Message from the CEO

“The year began at a high pace and during the second quarter we have maintained a high level of activity to get all the important parts in place for the successful commercialization of ISICORT®.”

Jonas Jönmark, CEO, AcuCort AB
August 12, 2022

We make good drugs better

AcuCort develops innovative treatments based on existing and well-documented substances in treatment areas where there is a high unmet medical need and commercial interest in new drugs that add benefits such as simplicity of administration.